10th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

VIENNA, 17-19 NOVEMBER, 2010

www.ifmad.org

Final Programme
SCIENTIFIC COMMITTEE

Chairman
Siegfried Kasper (Austria)

Co-Chairman
Stuart A. Montgomery (United Kingdom)

Scientific Advisers
C. Allgulander (Sweden), C.A. Altamura (Italy), C. Arango (Spain), D. Baldwin (United Kingdom), M. Bauer (Germany), P. Boyer (Canada), G. Burrows (Australia), G.B. Cassano (Italy), K. Demyttenaere (Belgium), J. Den Boer (The Netherlands), T. Dinan (Ireland), E. Eriksson (Sweden), N. Fineberg (United Kingdom), T. Higuchi (Japan), S.H. Kennedy (Canada), J.P. Lépine (France), M. Maj (Italy), A.A. Mathé (Sweden), J. Mendlewicz (Belgium), H.J. Möller (Germany), S. Pallanti (Italy), G. Papadimitriou (Greece), G. Papakostas (USA), Z. Rihmer (Hungary), A.F. Schatzberg (USA), D.J. Stein (South Africa), T. Suppes (USA), E. Vieta (Spain), L. Von Knorring (Sweden), D. Winkler (Austria), S. Yamawaki (Japan), J. Zohar (Israel)

IMPORTANT ADDRESSES

Organizing Secretariat
Publi Créations
74, Bd d’Italie - 98000 Monte-Carlo - Monaco
Ph. +377 97973555 - Fax +377 97973550
E-mail: ifmad@publiccreations.com - Website: www.ifmad.org

Forum Venue
Hotel HILTON
Am Stadtpark 1, Vienna,
Austria A - 1030
Tel: 43-1-717000
Franz Werfel (Gallery):
Slide preview Room

Prefunction area:
Exhibition booths, Coffee breaks & Lunches

Park 1 & 2: Auditorium

Park 3: Coffee breaks & Posters
It is our pleasure to welcome you in Vienna to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD).

IFMAD has become an important Forum for the exchange of ideas on the latest developments in psychiatric treatments where international experts can address in an informal atmosphere some of the important topics in the field of mood and anxiety disorders. The meetings are particularly valued for the high quality of the scientific contributions and the opportunity for focused discussion of new data presented in a constructive and productive environment.

Attendees at previous meetings have appreciated the very efficient and agreeable formula provided by IFMAD meetings for keeping up to date with current treatment issues. We look forward to renewing old acquaintances at the next meeting, which will be held in Budapest (9-11 November 2011) and to welcoming an even wider and international audience.

We are pleased to welcome you in Vienna and have you with us again this year.

Siegfried Kasper,  
Chairman

Stuart A. Montgomery,  
Co-Chairman

The Organising Committee express their gratitude to the following Companies

ASTRAZENECA
LUNDBECK A/S
PIERRE FABRE MEDICAMENTS
PFIZER LIMITED
for their contribution as Sponsor of Symposia

WISEPRESS LTD
for their participation in the exhibition
<table>
<thead>
<tr>
<th>Wednesday, November 17</th>
<th>Thursday, November 18</th>
<th>Friday, November 19</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>09.00/10.30</strong></td>
<td><strong>09.00/10.30</strong></td>
<td><strong>09.00/10.30</strong></td>
</tr>
<tr>
<td>Examining opportunities for increasing treatment success in depression and anxiety disorders</td>
<td>Controversies in resistant depression</td>
<td></td>
</tr>
<tr>
<td><strong>10.30/11.00</strong></td>
<td><strong>10.30/11.00</strong></td>
<td></td>
</tr>
<tr>
<td>Coffee break</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td><strong>11.00/12.30</strong></td>
<td><strong>11.00/12.30</strong></td>
<td></td>
</tr>
<tr>
<td>Treatment of Depression with Comorbidity</td>
<td>First line treatments post Cipriani</td>
<td></td>
</tr>
<tr>
<td><strong>12.30/13.30</strong></td>
<td><strong>12.30/13.30</strong></td>
<td></td>
</tr>
<tr>
<td>Lunch</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td><strong>13.30/15.00</strong></td>
<td><strong>13.30/14.30</strong></td>
<td></td>
</tr>
<tr>
<td>Is bipolar depression different from unipolar depression?</td>
<td>Augmentation in major depressive disorder - Reviewing the role for atypical antipsychotics</td>
<td></td>
</tr>
<tr>
<td><strong>14.30/16.00</strong></td>
<td><strong>14.30/16.00</strong></td>
<td></td>
</tr>
<tr>
<td>How can we overcome the stigma against treatment</td>
<td>Treatment mechanism in OCD</td>
<td></td>
</tr>
<tr>
<td><strong>16.00/16.30</strong></td>
<td><strong>16.00/16.15</strong></td>
<td></td>
</tr>
<tr>
<td>Coffee break</td>
<td>End of meeting</td>
<td></td>
</tr>
<tr>
<td><strong>16.30/18.00</strong></td>
<td><strong>16.30/18.00</strong></td>
<td></td>
</tr>
<tr>
<td>GAD as an obstacle to successful management of other psychiatric conditions</td>
<td>The noradrenergic symptom cluster in depression</td>
<td></td>
</tr>
<tr>
<td><strong>18.00/19.00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening Ceremony</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NB: This agenda is subject to change
### 14.30 - 16.00  SO 01 - HOW CAN WE OVERCOME THE STIGMA AGAINST TREATMENT

**Chair:** Elias Eriksson (Sweden), Carlo A. Altamura (Italy)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SO 0101</td>
<td>How can we neutralise the stigma of the treatment of depression</td>
<td>Jiri Raboch (Czech Republic)</td>
</tr>
<tr>
<td>SO 0102</td>
<td>The need for early onset treatments in depression and anxiety</td>
<td>Carlo A. Altamura (Italy)</td>
</tr>
<tr>
<td>SO 0103</td>
<td>Stigma against PMDD caused by regulatory action</td>
<td>Elias Eriksson (Sweden)</td>
</tr>
</tbody>
</table>

### 16.00 - 16.30  Coffee break

### 16.30 - 18.00  SO 02 - GAD AS AN OBSTACLE TO SUCCESSFUL MANAGEMENT OF OTHER PSYCHIATRIC CONDITIONS

**Chair:** Siegfried Kasper (Austria)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SO 0201</td>
<td>Preclinical work in anxiety: Latest insights</td>
<td>Johan A. Den Boer (The Netherlands)</td>
</tr>
<tr>
<td>SO 0202</td>
<td>Concurrent anxiety: Increasing the burden of other psychiatric disorders</td>
<td>Hans-Jürgen Möller (Germany)</td>
</tr>
<tr>
<td>SO 0203</td>
<td>Optimizing treatment in the presence of anxiety</td>
<td>Siegfried Kasper (Austria)</td>
</tr>
</tbody>
</table>

*Symposium sponsored by an unrestricted educational grant from Pfizer Limited*

### 18.00 - 19.00  Opening Ceremony
09.00 - 10.30  **SO 03 - EXAMINING OPPORTUNITIES FOR INCREASING TREATMENT SUCCESS IN DEPRESSION AND ANXIETY DISORDERS**

Chair: *Siegfried Kasper (Austria)*

- **SO 0301** Therapeutic drug monitoring of antidepressants: controversies and possibilities  
  *Gerald Zernig (Austria)*

- **SO 0302** Prioritising safety and efficacy in the treatment of elderly patients  
  *Eva Topinková (Czech Republic)*

- **SO 0303** Is the choice of antidepressant a major factor in attaining the treatment goal?  
  *Stuart Montgomery (UK)*

- **SO 0304** Treatment myths - a panel discussion  
  *Siegfried Kasper (Austria)*

*Symposium sponsored by an unrestricted educational grant from H. Lundbeck A/S*

10.30 - 11.00  **Coffee break**

11.00 - 12.30  **SO 04 - TREATMENT OF DEPRESSION WITH COMORBIDITY**

Chair: *Cristina Sampaio (Portugal)*  
*Jean-Pierre Lépine (France)*

- **SO 0401** Treatment of Parkinsons disease and depression  
  *Cristina Sampaio (Portugal)*

- **SO 0402** Influence of comorbid anxiety disorders on outcome in major depression  
  *David Baldwin (UK)*

- **SO 0403** Pharmacotherapy of neuropsychiatric manifestations of HIV/AIDS  
  *Christer Allgulander (Sweden)*

12.30 - 13.30  **Lunch**
13.30 - 15.00  SO 05 - IS BIPOLAR DEPRESSION DIFFERENT FROM UNIPOLAR DEPRESSION?
Chair: David Baldwin (UK), Eduard Vieta (Spain)

SO 0501  Symptom profile and outcome in bipolar and unipolar depression
Jules Angst (Switzerland)

SO 0502  A review of the evidence for monotherapy in bipolar depression
Eduard Vieta (Spain)

SO 0503  Augmentation strategies for bipolar and unipolar depression
Michael Bauer (Germany)

15.00 - 16.00  SO 06 - DEBATE: DO THE SUICIDE RESTRICTIONS ON ANTIDEPRESSANTS DO MORE HARM THAN GOOD?
Chair: Stuart Montgomery (UK)
Pro: Zoltan Rihmer (Hungary)
Contra: Karl Broich (Germany)

16.00 - 16.30  Coffee break

16.30 - 18.00  SO 07 - THE NORADRENERGIC SYMPTOM CLUSTER IN DEPRESSION
Chair: Stuart Montgomery (UK)

SO 0701  Introduction: What is the noradrenergic symptom cluster?
Stuart Montgomery (UK)

SO 0702  The increasing burden of depressive disorder
Jean-Pierre Lépine (France)

SO 0703  The noradrenergic symptom cluster - clinical expression and neuropharmacology
Pierre Blier (Canada)

SO 0704  Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Siegfried Kasper (Austria)

Symposium sponsored by an unrestricted educational grant from Pierre Fabre Medicaments
FRIDAY, 19 November 2010

09.00 - 10.30  SO 08 - CONTROVERSIES IN RESISTANT DEPRESSION
Chair: Daniel Souery (Belgium)  
Alessandro Serretti (Italy)

SO 0801  Resistant depression state or trait: genetic and clinical evidence?  
Alessandro Serretti (Italy)

SO 0802  Do current guidelines interfere with identifying and treating resistant depression  
Stuart Montgomery (UK)

SO 0803  Advances in the treatment of resistant depression  
Daniel Souery (Belgium)

10.30 - 11.00  Coffee break

11.00 - 12.30  SO 09 - FIRST LINE TREATMENTS POST CIPRIANI
Chair: Hans Jürgen Möller (Germany)  
Naomi Fineberg (UK)

SO 0901  Multiple treatments meta-analysis of antidepressants for major depression: strengths and weaknesses?  
Andrea Cipriani (Italy)

SO 0902  Mixed-treatments comparison meta-analysis of antidepressants: implications for everyday clinical practice  
Corrado Barbui (Italy)

SO 0903  Are direct double-blind comparisons the best tests of superiority?  
Hans-Jürgen Möller (Germany)

12.30 - 13.30  Lunch
13.30 - 14.30  **SO 10 - AUGMENTATION IN MAJOR DEPRESSIVE DISORDER – REVIEWING THE ROLE FOR ATYPICAL ANTIPSYCHOTICS**

Chair: *Stuart Montgomery (UK)*

**SO 1001**  When treatment fails - a review of the evidence for atypical antipsychotics as an augmentation strategy in MDD

*Michael Bauer (Germany)*

**SO 1002**  Symptom control - an important outcome for depressed patients

*Borwin Bandelow (Germany)*

*Symposium sponsored by an unrestricted educational grant from AstraZeneca*

14.30 - 16.00  **SO 11 - TREATMENT MECHANISMS IN OCD**

Chair: *Michael Bauer (Germany) Naomi Fineberg (UK)*

**SO 1101**  Augmentation strategies in resistant OCD

*Stefano Pallanti (Italy)*

**SO 1102**  Relevance of cognitive dimensions in the treatment of OCD

*Naomi Fineberg (UK)*

**SO 1103**  Do imaging studies improve treatment strategies in OCD?

*Martijn Figee (The Netherlands)*

16.00 - 16.15  **End of meeting**
P 01. The effects of typical and atypical anti-psychotics on inducing obsessive-compulsive symptoms in patients with schizophrenia
A. Afkham Ebrahimi
Iran University of Medical Sciences, Tehran, Iran

P 02. Some therapeutic approaches to anxiety disorders in late life
M. Arnaoudova-Jekova
Medical University, Varna, Bulgaria

P 03. The many faces of anxiety in later life
M. Arnaoudova-Jekova
Medical University, Varna, Bulgaria

P 04. Effects of cholinergic system of medial prefrontal cortex on anxiety-related behaviors
A. Bakhtiari, J. Solati, A.A. Salari
Department of Biology, Faculty of Science, Islamic Azad University, Karaj Branch, Karaj, Iran

P 05. A double-blind, placebo-controlled study of augmentation with LY2216684 for major depressive disorder patients who are partial responders to selective serotonin reuptake inhibitors
S. Ball, M. Dellva, D. D'Souza, L. Marangell, J. Russell, C. Goldberger
Eli Lilly and Company, Indianapolis, USA

P 06. Pooled analysis of the efficacy of adjunctive quetiapine XR in patients with major depressive disorder and high or low levels of baseline anxiety
B. Bandelow¹, M. Bauer², E. Vieta³, N. El-Khaldi⁴, M. Udd⁵, U. Gustafsson⁵, H. Eriksson⁵
¹University of Goettingen, Department of Psychiatry and Psychotherapy, Goettingen, Germany, ²University Hospital Carl Gustav Carus, Department of Psychiatry and Psychotherapy, Dresden, Germany, ³University of Barcelona, Bipolar Disorders Program, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain, ⁴Alpine Clinic, Department of Psychiatry, Lafayette, USA, ⁵AstraZeneca, R&D, Södertälje, Sweden

P 07. Predictive factors of remission for treatment-resistant major depressive disorder (MDD) during treatment with extended-release quetiapine fumarate (quetiapine XR)
M. Bauer¹, S. Kasper², L. Dell'Ossono³, W. Pichot⁴, B.T. Baune⁴, J. Köhler⁴, L. Jørgensen⁷, E. Dencker-Vansvik⁷, S. Montgomery⁸
¹University Hospital Carl Gustav Carus, Technische Universität Dresden, Department of Psychiatry and Psychotherapy, Dresden, Germany, ²Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria, ³University of Pisa, Department of Psychiatry, Pharmacology, Neurobiology and Biotechnology, Pisa, Italy, ⁴University of Liège, Psychiatric Unit, Liège, Belgium, ⁵James Cook University, Psychiatry & Psychiatric Neuroscience, Queensland, Australia, ⁶AstraZeneca, Medical Department, Wedel, Germany, ⁷AstraZeneca, Department of Medical Affairs, Södertälje, Sweden, ⁸Imperial College, London, UK

P 08. Adjunctive quetiapine XR and its effects on sleep disturbance and quality: a pooled analysis from two acute studies in MDD
M. Bauer¹, R.S. McIntyre², J. Szamoci³, H. Eriksson³
¹University Hospital Carl Gustav Carus, Department of Psychiatry and Psychotherapy, Dresden, Germany, ²University Health Network, University of Toronto, Department of Psychiatry, Toronto, Canada, ³AstraZeneca, R&D, Södertälje, Sweden

P 09. Long-term adjunctive aripiprazole therapy for treatment-resistant bipolar disorder
K. Bongjin
Department of Psychiatry, Seoul National University, Bundang Hospital, Seoul, South Korea
P 10. Improvement of sexual function in depressed outpatients treated with milnacipran
M. Briley¹, R. Moreno²
¹NeuroBiz Consulting & Communication, Castres, France, ²Mood Disorders Unit - Department of Psychiatry, University of São Paulo Medical School, Sao Paulo, Brazil.

P 11. Is poor Insight Obsessive-Compulsive Disorder a distinct subtype?
National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.

P 12. Plasma serotonin level of vietnam war veterans with posttraumatic stress disorder and symptom severity
M. Chung¹, S. Kang², T. Lee¹, M. Lee¹
¹Seoul Veterans Hospital, Seoul, South Korea, ²Choonchun National Mental Hospital, Choonchun, South Korea

P 13. Demographic, clinical and treatment-related resistance features of Treatment Resistant Depression subjects: preliminary results
L. Cosentino, N. Bartolomei, F. Luchini, B. Berti, F. Casamassima, L. Palagini, L. Lattanzi, M. Mauri
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Pisa, Italy

P 14. Antipsychotics in treatment-resistant obsessive-compulsive disorder - a systematic review
M. Dold, R. Lanzenberger, M. Aigner
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

P 15. The Role of the 5-HT₂C Receptor Sub-type in preclinical models of Obsessive-Compulsive Disorder
N. Fineberg, A. Brown
National Specialist Service for Obsessive Compulsive Disorders, Hertfordshire Partnership NHS Foundation Trust, Queen Elizabeth II Hospital, Welwyn Garden City, UK

P 16. Treating depression in parkinson’s disease with electroconvulsive therapy
E. Guertzenstein, J.C.M. Nóbrega, M.J. Teixeira
Division of Neurosurgery, Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

P 17. Identifying CYP2D6 intermediate and poor metabolizers among schizophrenic patients with respect to therapeutical response
J. Jurica¹, R. Bartecék², O. Zendulka¹, T. Kaspárek², E. Flodrova², A. Sulcova¹
¹Department of Pharmacology, Faculty of Medicine, Masaryk University, ²Department of Psychiatry of Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³Department of Medical genetics, Faculty Hospital Brno, Czech Republic

P 18. How well do randomized controlled trial data generalize to real world clinical practice settings? Comparison of two generalized anxiety disorder (GAD) studies
S. Kasper¹, M. Brasser², E. Schweizer³, S. Donevan¹, G. Lyndon⁴, R. Prieto⁶
¹Medical University of Vienna, Vienna, Austria, ²Pfizer Pharma GmbH, Berlin, Germany, ³Paladin Consulting Group, Hoboken, NJ, USA, ⁴Pfizer Inc., New York, NY, USA, ⁵Pfizer Ltd., Tadworth, Surrey, UK, ⁶Pfizer España, Madrid, Spain
P 19. Is silexan an anxiolytic drug?
S. Kasper¹, S. Klement²
¹Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, ²Schwabe Company, Germany

P 20. The efficacy of agomelatine in previously treated depressed patients
S. Kasper¹, G. Hajak²
¹Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, ²Department of Psychiatry, Psychosomatics and Psychotherapy, University of Regensburg, Germany

P 21. Prevalence and symptom characteristics of depression in schizophrenia patients
D. Lee¹, D.U. Bek²
¹Bongseng Memorial Hospital, Busan, South Korea, ²Dongrae Bongseng Hospital, Busan, South Korea

P 22. Trauma induced major depression: associated disability
M. Livingston⁴, A.J. Showman¹, H.M. Livingston²
¹Southern General Hospital and University of Glasgow, Glasgow, UK, ²Royal Alexandra Hospital, Paisley, UK

P 23. Brain Neuropeptide Y (NPY) is a marker of PTSD in an animal model
AA. Mathé¹, H. Cohen², T. Liu¹, M.A. Matar², J. Zohar³
¹Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, ²Mental Health Center, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel, ³The Chaim Sheba Medical Center, Sacker Medical School, Tel-Aviv University, Israel

P 24. Comorbid mood and anxiety disorders in adult ADHD patients
Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria

P 25. Anxiety and depression symptoms in children-commorbidity with learning disabilities
A. Michopoulou, M. Mavilidi, D. Thomas, K. Karmiri, A. Patrou, A. Koutsoukou-Arygraki
Pentelis Children Hospital, Athens, Greece

P 26. Efficacy of pregabalin in elderly patients with generalized anxiety disorder (GAD) who present with high levels of insomnia
S. Montgomery¹, Y. Xu², E. Schweizer³, S. Donevan², G. Lyndon⁴, R. Prieto⁵
¹Imperial College School of Medicine, University of London, London, UK, ²Pfizer Inc., New York, NY, USA, ³Paladin Consulting Group, Hoboken, NJ, USA, ⁴Pfizer Ltd., Tadworth, Surrey, UK, ⁵Pfizer España, Madrid, Spain

P 27. Personality and antidepressant adherence: a pilot study
S. Monzon¹, M. Gilli¹, M.J. Serrano¹, N. Bauza¹, M. Vives¹, M. Garcia-Toro¹, J. Salva¹, C. Mateu², C. Vicens³, F. Bestard², T. Ballester², M. Roca¹
¹Institut Universitari d’Investigació en Ciències de la Salut (lunics), University of Balearic Islands, Palma, Spain, ²Red de Investigación en Actividades Preventivas y Promoción de la Salud (Rediapp), Madrid, Spain, ³Centro de Salud Son Serra-la viletà. IB-Salut, Palma, Spain, ⁴Centro de Salud Son Goteu. IB-Salut, Palma, Spain, ⁵Centro de Savud Salud Escola Graduada. IB-Salut, Palma, Spain

P 28. Are there phenotypic differences in adults with early and late onset OCD?
J. C. Narayanaswamy, B. Viswanath, A. V. Cherian, S. Bada Math, Y. C. Janardhan Reddy
National Institute of Mental Health And Neurosciences (NIMHANS), Bangalore, India

P 29. Plasma biomarkers to diagnose major depressive disorder
Y. Ohashi¹, K. Shinoda¹, H. Sato¹, T. Ishikawa¹, N. Kawamura²
¹Human Metabolome Technologies, Inc., Tsuruoka, Japan, ²National Center of Neurology and Psychiatry, Tokyo, Japan
P 30. Designing a comparative study of escitalopram versus risperidone for the treatment of behavioral and psychological symptoms in Alzheimer’s disease
D. Paleacu, I. Plopsky, S. Tadger, Y. Barak
Abarbanel Mental Health Center associated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

P 31. Prescription of antipsychotics in inpatients with MDD 2000 and 2007 - results from the AMSP International Pharmaco vigilance Project
K. Papageorgiou1, A. Konstantinidis1, R. Grohmann2, A. Horvath3, R. Engel3, S. Kasper1
1Department of Biological Psychiatry, Medical University of Vienna, Vienna, Austria, 2Department of Psychiatry, Ludwig Maximilians University, Munich, Germany, 3Psychiatric Private Clinic Sanatorium Kilchberg/Zurich, Zurich, Switzerland

P 32. The reliability and validity of WHOQOL in patients with breast cancer: physical domain and depression
S.I. Han, Y.W. Jeon, E.J. Park
Department of Psychiatry, Incheon St. Mary’s Hospital, The Catholic Universe of Korea

P 33. Public attitudes towards depression and psychiatric medication: barriers to treatment
L.E. Peppou, I. Karayanni, G. Skalkotos, D. Kolostoumpis, A. Komporozos, M. Economou
University Mental Health Research Institute (UMHRI) - Anti-Stigma Programme, Athens, Greece

P 34. Early vs. delayed switch to duloxetine in patients with major depressive disorder not exhibiting early improvement with escitalopram: a double-blind randomized study
I. Romera1, V. Perez2, J.M. Menchon3, A. Schacht4, R. Papen5, D. Neuhauser6, I. Gilaberte1
1Eli Lilly and Company, Medical Department, Madrid, Spain, 2Hospital de Sant Pau i de la Santa Creu Barcelona, Spain, 3Hospital Universitari de Bellvitge, Hospi tale de Llobregat, Barcelona, Spain, 4Eli Lilly and Company, Global Statistical Sciences, Bad Homburg, Germany, 5Eli Lilly and Company, Bad Homburg, Germany, 6Eli Lilly and Company, Vienna, Austria

P 35. Efficacy and safety of zolpidem tartrate sublingual tablet for as-needed treatment of middle-of-the-night (MOTN) insomnia
T. Roth1, N. N. Singh2, F. Steinberg3, A. Krystal4
1Henry Ford Hospital, Detroit, MI, 2Transcept Pharmaceuticals, Inc, Pt Richmond, CA, 3Chief Medical Consultant to Transcept Pharmaceuticals, Inc., Evanston, IL, 4Duke University, Durham, NC, USA

P 36. Treatment of middle of the night insomnia: current therapeutic approaches
T. Roth1, N. N. Singh2, D. Cooke2
1Henry Ford Hospital, Detroit, MI, 2Transcept Pharmaceuticals, Inc., Pt Richmond, CA, USA

P 37. Intra-peritoneal injection of salmonella typhimurium LPS affect anxiety behaviors and serum corticosterone level in pregnant mice and its male offspring
A.A. Salari1, J. Solati2, B. Tabaraie3, B. Rashidieh1, M. Enayati1
1Department of Biology, Young Researchers Club, Islamic Azad University, Karaj Branch, Karaj, Iran, 2Department of Biology, Faculty of Science, Islamic Azad University, Karaj Branch, Karaj, Iran, 3Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran

P 38. Multitracer pet imaging of the serotonergic system
M. Savili1, A. Bauer3, D. Häusler3, T. Kroll2, A. Hahn1, F. Rattay4, M. Mitterhauser3, W. Wadsak3, S. Kasper1, R. Lanzenberger1
1Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, 2Institute of Neuroscience and Medicine (INM-2), Research Centre Jülich, Vienna, Austria, 3Department of Nuclear Medicine, Medical University of Vienna, Vienna, Austria, 4Institute for Analysis and Scientific Computing, Vienna University of Technology, Vienna, Austria
P 39. 3D brain SPECT imaging as an aid in the management of resistant depression
H. Schneider1, J. Thornton2, R. Tarzwell3, M. Freeman4, M. Mclean5, M. Van Lierop6
1Sheppard Clinic, Toronto, 2Rossiter-Thornton Associates, Toronto, 3University of British Columbia, Vancouver, 4University of Toronto, Toronto, 5Dr. M. McLean, MD, Toronto, 6Dr. M. van Lierop, MD, Toronto, Canada

P 40. Genome wide association scan of co-morbid anxiety in MDD.
A. Schosser1,2, M.Y. Ng1, A.W. Butler1, R. Uher1, S. Cohen-Woods1, N. Craddock2, M. Owen2, K.J. Aitchison1, G. Breen1, I. Craig1, A.E. Farmer1, C.M. Lewis1, P. McGuffin1
1MRC SGDP Centre, Institute of Psychiatry, King’s College London, UK, 2MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, Cardiff University, UK

P 41. Ruptured aneurysm involving right basal ganglia with manic and psychotic features.
S. Thanasan
Department of Psychological Medicine, University Malaya, Kuala Lumpur, Malaysia

P 42. Prevalence of depression in cancer patients: cultural influence
C.G. Ng, S. Thanasan, N.Z. Zainal
University Malaya, Kuala Lumpur, Malaysia

P 43. Altered quality of life in epilepsy: significance of interictal depression
K. Todorova-Nenova
MHAT St.Marina, I Psychiatric Clinic, Varna, Bulgaria

P 44. Influence of depression, sociodemographic and seizure-related variables on quality of life of adults with epilepsy
K. Todorova-Nenova
MHAT St.Marina, I Psychiatric Clinic, Varna, Bulgaria

P 45. Improving compliance and treatment outcome in bipolar and schizophrenic patients by using short message text service (SMS).
E. Van Gent1, E. Knoppert Van Der Klein2
1Faneurop, department psychiatry, Arnhem, The Netherlands, 2Rivierduinen, GGZ Rijnstreek, Alphen a/d Rijn, The Netherlands

P 46. Psychiatrists’ awareness of adherence to antipsychotic medication in bipolar disorder: results from a survey conducted across eight European countries
E. Vieta1, J-M Azorin2, M. Bauer3, S. Frangou4, G. Perugi5, G. Martinez6, A. Schreiner7
1Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain, 2Sainte Marguerite Hospital, SHU Psychiatrie Adultes, University of Marseilles, Marseille, France, 3Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, 4Section of Neurobiology of Psychosis, Institute of Psychiatry, King’s College London, London, UK, 5Department of Psychiatry, University of Pisa, Pisa, Italy, 6Janssen-Cilag EMEA Medical Affairs, Madrid, Spain, 7Janssen-Cilag EMEA Medical Affairs, Neuss, Germany
Audio-Visual Facilities
Speakers must go to the preview room in order to validate and download their presentation files, at least forty minutes before the beginning of the sessions. Please respect this schedule, otherwise, the performance of the received presentations is not guaranteed. We cannot accept presentations delivered in room directly (without previewing). Coffee breaks and midday are the busiest time in the preview room. So we recommend you to come to the preview early in the morning or during other presentations. An hostess will guide and assist the speakers for checking and downloading their presentation files.

European Accreditation
15 UEMS credits have been granted to this Congress. UEMS credits are recognized by the American Medical Association for conversion to AMA PRA Category 1 Credit.

Certificate of Attendance
A certificate of attendance is provided, on request, at the registration desk on the last day of the Forum.

The “10th International Forum on Mood and Anxiety Disorders” is held at the Hilton Hotel Vienna, Am Stadtpark 1, 1030 Vienna, Austria from 17-19 November 2010.

Admission (Badges)
The participant’s name badge is provided at the registration desk. All participants are requested to wear the badge throughout the Forum. Only badge holders are admitted to the appropriate sessions, exhibition and social events.

Coffee breaks and Lunches
During the Forum sessions, coffee breaks and lunches are served free of charge to all registered participants, wearing the badge.

Electricity
The standard voltage in Austria is 220 V. The Austrian network supply a frequency of 50Hz. Plugs are continental-style two-pins.

Currency
The official currency in Austria is the Euro.

Insurance
The Forum organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Forum participants and accompanying persons, either during
or as a result of the Forum. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice upon Registration to the Forum and booking of your travel.

**Language**
The official language of the Forum is English. No simultaneous translation is provided.

**Mobile phones**
Delegates are kindly requested to switch their mobile phones off during the scientific sessions.

**Secretariat Desk**
The Secretariat desk is and stay open on Wednesday, 17th November 2010 and stay open all through the Forum as follow:

- **Wednesday, November 17** 12h00 - 18h00
- **Thursday, November 18** 08h15 - 18h00
- **Friday, November 19** 08h15 - 16h15

**Smoking Policy**
The 10th International Forum on Mood and Anxiety Disorders is a non-smoking venue. Forum participants are kindly requested to refrain from smoking in the Forum venue, including the exhibition area and restrooms.

**Tips**
Service is usually included in the prices in bars and restaurants, but tips are welcome.

**Useful Telephone Numbers**
- Ambulance and Emergency Services 144
- Emergency Doctor 141
- Euro Emergency number 112
- Police 133
- Fire department 122
- Night and weekend dental services 5 12 20 78
- Pharmacies open nights and Sunday 1550

**Other Useful Numbers**
- Vienna International Airport: infoline **+43 7007 22233** (24 hours) www.viennairport.com
- Taxi: **+43 699 19780413**
The 11th International Forum on Mood and Anxiety Disorders will be held in Budapest, Hungary from 9 -11 November, 2011
Cipralex - the power to tackle depression at its core

Leaving no one behind

Presentation: “Cipralex”. Tablets containing 5, 10, 15 or 20 mg escitalopram (as oxalate).
Indications: Major depression. Generalised anxiety disorder. Panic disorder. Social anxiety disorder. Obsessive compulsive disorder. Dosage: Usual dose is 10 mg daily. Maximum dose 20 mg daily. In elderly (≥65 years), in panic disorder patients and in patients with reduced hepatic function an initial dose of 5 mg daily is recommended. Caution in patients with severely reduced renal function. Not recommended in children and adolescents (<18 years). When stopping treatment the dose should be gradually reduced over a period of one or two weeks. Contraindications: Hypersensitivity to escitalopram. Concomitant treatment with MAOIs. Pregnancy and lactation: Careful consideration prior to use in pregnant women. Breast-feeding women should not be treated. Precautions: The special warnings and precautions which apply to the class of SSRIs. Drug interactions: MAOIs, serotoninergic drugs, drugs lowering the seizure threshold, lithium, tryptophan, St. John’s Wort, anticoagulants, drugs metabolised mainly by enzymes CYP 2D6 or 2C19. Adverse events: Most frequent during the first or second week, very common is nausea, less frequent is adverse events comprising to the SSRI class. Overdosage: Doses between 400 mg and 800 mg of escitalopram alone have been taken without any severe symptoms. Consult full prescribing information before prescribing. H. Lundbeck A/S, Copenhagen, Denmark. Date of preparation: February 2010